FIGURE 6.

Ability of dualsteric CB₂R ligand JR64a to decrease the inflammatory phenotype of LPS/TNFα stimulated HMC3 cells. Panels (A) and (B) show the effects of JR64a on the release of pro-and anti-inflammatory interleukines IL-6 and IL-10, respectively. Panels (C) and (D) show the effects produced in the same experimental setting by administering CB₂R selective orthosteric agonist LV62 alone or in combination (1:1) with the CB₂R PAM EC21a. Bars represent the release (pg/ml) of ILs in the presence of the compounds. Data represent mean ± SEM from n = 3 independent experiments performed in duplicate. Statistical analysis was performed by ordinary one-way ANOVA followed by Tukey’s multiple comparison test. ^### p < 0.005 vs. control cells; *p < 0.05, **p < 0.01 and ***p < 0.005 vs. LPS/TNFα treated cells.